By indication / Gynaecological cancer
Gynaecological cancer
8 imaging agents and 9 therapeutic agents reported for this indication. Stage reflects how far each has been taken, not what is available in any given country.
Imaging
| Agent | Isotope | Stage | Syntheses |
|---|---|---|---|
| [11C]PS13 | C-11 | first-in-human | 1 |
| [18F]FB-2BD42 | F-18 | — | 1 |
| [89Zr]Zr-Df-pertuzumab-800CW | Zr-89 | — | 1 |
| [89Zr]Zr-TROP2 | Zr-89 | preclinical | 1 |
| [18F]ef5 | F-18 | — | |
| [18F]FB-4AH29 | F-18 | preclinical | |
| [18F]FluorThanatrace | F-18 | — | |
| [68Ga]Ga-FAPI-74 | Ga-68 | — |
Therapy
| Agent | Isotope | Stage | Syntheses |
|---|---|---|---|
| [177Lu]Lu-DOTA-trastuzumab | Lu-177 | clinical evaluation | 5 |
| [212Pb]Pb-212-TCMC-trastuzumab | Pb-212 | Phase I clinical trial (first-in-human) | 5 |
| [177Lu]Lu-FAP-2286 paired with [68Ga]Ga-FAP-2286 | Lu-177 | first-in-human | 4 |
| [212Pb]Pb-TCMC-chOI-1 | Pb-212 | preclinical study | 4 |
| [225Ac]Ac-225-PRIT | Ac-225 | preclinical study | 3 |
| [90Y]Y-90-FF-21101 | Y-90 | phase I/II clinical trial | 2 |
| [211At]At-211-MX35 | At-211 | — | 2 |
| [225Ac]Ac-DOTA-2Rs15d | Ac-225 | preclinical study | 1 |
| [225Ac]Ac-mcp-PEG8-Tz | Ac-225 | Reported once | 1 |
Have a question?Reagents, modules, introductions to manufacturers or to specialists in your region — tell us what you need.
Get in touch